{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:52:47Z","timestamp":1740174767631,"version":"3.37.3"},"reference-count":16,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":255,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Antipsychotics improve symptoms associated with schizophrenia and bipolar disorder. To improve medication adherence and decrease the need for hospitalization, many antipsychotics have been developed into long-acting injectable (LAI) formulations. Though mirror-image studies have demonstrated significantly decreased hospitalization rates with LAI use, there is limited data when suboptimal use parameters are present.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective chart review was conducted on patients who were administered aripiprazole monohydrate long-acting injectable (AM-LAI) in an adult mental health unit. Demographics and AM-LAI use parameters were analyzed descriptively. Endpoints compared the days between encounters pre and post AM-LAI administration and number of inpatient encounters between the 180 days pre and post AM-LAI administration. Effects of AM-LAI on inpatient encounters were analyzed using a Wilcoxon signed rank test with an alpha set to &amp;lt;0.05 for significance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-eight patients met inclusion criteria. Mean (\u00b1\u2009SD) age was 39.4 (11.4) years with 55.2% of the sample male. Most patients were diagnosed with schizophrenia or unspecified psychotic disorder and admitted involuntarily. The mean number of days from last admission to the date of initial AM-LAI administration was 109.3 (75.2), compared with 131.3 (69.8) days to next encounter (P\u2009=\u2009.044) post AM-LAI. Total inpatient encounters were also reduced (P\u2009=\u2009.004), although no differences in encounters for psychiatric reasons were detected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Use of AM-LAI was associated with a prolonged time to next inpatient encounter and reduced total inpatient encounters, however its use failed to demonstrate reductions in psychiatric encounters.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2019.07.258","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T17:05:00Z","timestamp":1562000700000},"page":"258-262","source":"Crossref","is-referenced-by-count":2,"title":["Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-508X","authenticated-orcid":false,"given":"Monica","family":"Aguilar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-9036","authenticated-orcid":false,"given":"Benjamin","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"2","key":"2020060307355570700_i2168-9709-9-4-258-b01","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/407171","article-title":"Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review","volume":"2012","author":"Zhornitsky","year":"2012","journal-title":"Schizophr Res Treatment"},{"issue":"4","key":"2020060307355570700_i2168-9709-9-4-258-b02","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40801-015-0043-4","article-title":"Costs and resource utilization among medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics","volume":"2","author":"Pesa","year":"2015","journal-title":"Drugs Real World Outcomes"},{"issue":"2 Suppl","key":"2020060307355570700_i2168-9709-9-4-258-b03","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2020060307355570700_i2168-9709-9-4-258-b04","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"issue":"2","key":"2020060307355570700_i2168-9709-9-4-258-b05","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials","volume":"28","author":"Fusar-Poli","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"issue":"8 Suppl","key":"2020060307355570700_i2168-9709-9-4-258-b06","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry","volume":"66","author":"Kane","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2020060307355570700_i2168-9709-9-4-258-b07","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40501-017-0115-z","article-title":"The use of long-acting injectable antipsychotics in schizophrenia","volume":"4","author":"Miyamoto","year":"2017","journal-title":"Curr Treat Options Psychiatry"},{"issue":"10","key":"2020060307355570700_i2168-9709-9-4-258-b08","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"2020060307355570700_i2168-9709-9-4-258-b09","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1185\/03007995.2014.915211","article-title":"Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia","volume":"30","author":"Lafeuille","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2020060307355570700_i2168-9709-9-4-258-b10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3111\/13696998.2014.979936","article-title":"Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis","volume":"18","author":"Kane","year":"2015","journal-title":"J Med Econ"},{"key":"2020060307355570700_i2168-9709-9-4-258-b11","doi-asserted-by":"publisher","first-page":"212301","DOI":"10.7573\/dic.212301","article-title":"Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis","volume":"5","author":"Sapin","year":"2016","journal-title":"Drugs Context"},{"issue":"12","key":"2020060307355570700_i2168-9709-9-4-258-b12","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1177\/0269881117735686","article-title":"Aripiprazole long-acting injection - a mirror image study of its effects on hospitalisation at one year","volume":"31","author":"Taylor","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"11","key":"2020060307355570700_i2168-9709-9-4-258-b13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/cer-2018-0068","article-title":"Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder","volume":"7","author":"Yan","year":"2018","journal-title":"J Comp Eff Res"},{"year":"2018","key":"2020060307355570700_i2168-9709-9-4-258-b14","article-title":"ABILIFY MAINTENA [package insert]"},{"issue":"3","key":"2020060307355570700_i2168-9709-9-4-258-b15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1185\/03007995.2015.1006356","article-title":"Initiation of aripiprazole once-monthly in patients with schizophrenia","volume":"31","author":"Raoufinia","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2020060307355570700_i2168-9709-9-4-258-b16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.9740\/mhc.2016.05.134","article-title":"and emergency room visits after initiation of long-acting injectable antipsychotics","volume":"6","author":"Heesch","year":"2016","journal-title":"Ment Health Clin [Internet]"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/4\/258\/2427670\/mhc_2019_07_258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/4\/258\/2427670\/mhc_2019_07_258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:26:00Z","timestamp":1731687960000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/4\/article-p258.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.07.258","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}